{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:42:21Z","timestamp":1791567741099,"version":"4.3.4"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Since its introduction in the 1980s, oocyte donation (OD) has been largely integrated into ART. Lately, both demand and the indications for OD have increased greatly. Oocyte donors are healthy and potentially fertile women undergoing voluntarily ovarian stimulation (OS). Selection of the optimal type of stimulation is of paramount importance in order to achieve the most favourable outcomes for the oocyte recipients, but most importantly for the safety of the oocyte donors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVE AND RATIONALE<\/jats:title>\n                  <jats:p>This is the first systematic review (SR) with the objective to summarize the current evidence on OS in oocyte donors. The scope of this SR was to evaluate the OD programme by assessing four different aspects: how to assess the ovarian response prior to stimulation; how to plan the OS (gonadotrophins; LH suppression; ovulation trigger; when to start OS); how to control for the risk of ovarian hyperstimulation syndrome (OHSS) and other complications; and the differences between the use of fresh versus vitrified donated oocytes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SEARCH METHODS<\/jats:title>\n                  <jats:p>A systematic literature search was conducted in May 2020, according to PRISMA guidelines in the databases PubMed and Embase, using a string that combined synonyms for oocytes, donation, banking, freezing, complications and reproductive outcomes. Studies reporting on the safety and\/or efficacy of OS in oocyte donors were identified. The quality of the included studies was assessed using ROBINS-I and ROB2. Meta-analysis was performed where appropriate. Data were combined to calculate mean differences (MD) for continuous variables and odd ratios (OR) for binary data with their corresponding 95% CIs. Heterogeneity between the included studies was assessed using I2 and tau statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OUTCOMES<\/jats:title>\n                  <jats:p>In total, 57 manuscripts were selected for the review, out of 191 citations identified. Antral follicle count and anti-M\u00fcllerian hormone levels correlate with ovarian response to OS in OD but have limited value to discriminate donors who are likely to show either impaired or excessive response. Five randomized controlled trials compared different type of gonadotrophins as part of OS in oocyte donors; owing to high heterogeneity, meta-analysis was precluded. When comparing different types of LH control, namely GnRH antagonist versus agonist, the studies showed no differences in ovarian response. Use of progesterone primed ovarian stimulation protocols has been evaluated in seven studies: the evidence has shown little or no difference, compared to GnRH antagonist protocols, in mean number of retrieved oocytes (MD 0.23, [95% CI 0.58\u20131.05], n\u2009=\u20092147; 6 studies; I2 = 13%, P =\u20090.33) and in clinical pregnancy rates among recipients (OR 0.87 [95% CI 0.60\u20131.26], n\u2009=\u20092260, I2 = 72%, P &amp;lt;\u20090.01). There is insufficient evidence on long-term safety for babies born. GnRH agonist triggering is the gold standard and should be used in all oocyte donors, given the excellent oocyte retrieval rates, the practical elimination of OHSS and no differences in pregnancy rates in recipients (four studies, OR 0.86, 95%CI 0.58\u20131.26; I2 = 0%). OS in OD is a safe procedure with a low rate of hospitalization after oocyte retrieval. The use of a levonorgestrel intrauterine device or a progestin contraceptive pill during OS does not impact the number of oocytes retrieved or the clinical pregnancy rate in recipients. Ultrasound monitoring seems enough for an adequate follow up of the stimulation cycle in OD. Use of fresh versus vitrified donated oocytes yielded similar pregnancy outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS<\/jats:title>\n                  <jats:p>This update will be helpful in the clinical management of OS in OD based on the most recent knowledge and recommendations, and possibly in the management of women under 35\u2009years undergoing oocyte vitrification for social freezing, owing to the population similarities. More clinical research is needed on OS protocols that are specifically designed for OD, especially in term of the long-term safety for newborns, effective contraception during OS, and treatment satisfaction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humupd\/dmab008","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T07:09:34Z","timestamp":1613632174000},"page":"673-696","source":"Crossref","is-referenced-by-count":36,"title":["Ovarian stimulation for oocyte donation: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-2612","authenticated-orcid":false,"given":"Francisca","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitario Dexeus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Racca","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitario Dexeus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitario Dexeus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos P","family":"Polyzos","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitario Dexeus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"2021070807505486800_dmab008-B1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.fertnstert.2006.05.049","article-title":"Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates","volume":"86","author":"Acevedo","year":"2006","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.fertnstert.2004.03.020","article-title":"Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles","volume":"82","author":"Acevedo","year":"2004","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.fertnstert.2018.03.022","article-title":"Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes","volume":"110","author":"Adeleye","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.fertnstert.2018.03.022","article-title":"Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes","volume":"110","author":"Adeleye","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B5","first-page":"CD001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807505486800_dmab008-B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/humupd\/dmr039","article-title":"Ovarian antral folliculogenesis during the human menstrual cycle: a review","volume":"18","author":"Baerwald","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2021070807505486800_dmab008-B8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/humrep\/dez034","article-title":"Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial","volume":"34","author":"Beguer\u00eda","year":"2019","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1472-6483(10)60200-3","article-title":"Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles","volume":"17","author":"Bodri","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B10","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.fertnstert.2009.08.036","article-title":"Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study","volume":"93","author":"Bodri","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.fertnstert.2010.06.068","article-title":"Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis","volume":"95","author":"Bodri","year":"2011","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B12","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/humrep\/del152","article-title":"Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial","volume":"21","author":"Bodri","year":"2006","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/humupd\/dmw006","article-title":"Investigating psychosocial attitudes, motivations and experiences of oocyte donors, recipients and egg sharers: a systematic review","volume":"22","author":"Bracewell-Milnes","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.fertnstert.2013.07.1992","article-title":"Effective method for emergency fertility preservation: random-start controlled ovarian stimulation","volume":"100","author":"Cakmak","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B16","first-page":"385","article-title":"Reproductive outcomes in oocyte donation cycles are associated with donor BMI","volume":"31","author":"Cardozo","year":"2016","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/09513590.2019.1707178","article-title":"Ovarian hyperstimulation syndrome following GnRH agonist trigger for final follicular maturation in a patient undergoing random start ovarian stimulation for egg-donation cycle with an inadvertent concomitant early pregnancy","volume":"36","author":"Castillo","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.rbmo.2011.11.006","article-title":"Triggering with GnRH agonist in oocyte-donation cycles: oestradiol monitoring is not necessary during ovarian stimulation","volume":"24","author":"Castillo","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B19","first-page":"i54","article-title":"Natural micronized progesterone versus GnRH antagonist in egg-donation cycles. An extended experience","volume":"35","author":"Castillo","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/09513590.2011.652244","article-title":"Triggering ovulation with 250 \u03bcg or 500 \u03bcg of r-hCG in oocyte donors treated with antagonist protocol has no effect on the number of mature oocytes retrieved: a randomized clinical trial","volume":"28","author":"Clua","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09513590.2015.1111330","article-title":"Obstetric and perinatal complications in an oocyte donation programme. Is it time to limit the number of embryos to transfer?","volume":"32","author":"Clua","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/09513590.2019.1653845","article-title":"Single or double embryo transfer? Decision-making process in patients participating in an oocyte donation program","volume":"36","author":"Clua","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B23","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.fertnstert.2015.08.020","article-title":"Six years\u2019 experience in ovum donation using vitrified oocytes: report of cumulative outcomes, impact of storage time, and development of a predictive model for oocyte survival rate","volume":"104","author":"Cobo","year":"2015","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B24","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/humrep\/deq146","article-title":"Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial","volume":"25","author":"Cobo","year":"2010","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B25","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/humrep\/deaa178","article-title":"Efficiency and efficacy of vitrification in 35 654 sibling oocytes from donation cycles","volume":"35","author":"Cornet-Bartolom\u00e9","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.fertnstert.2016.10.002","article-title":"Cryopreserved oocyte versus fresh oocyte assisted reproductive technology cycles, United States, 2013","volume":"107","author":"Crawford","year":"2017","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.rbmo.2017.03.003","article-title":"Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study","volume":"34","author":"Cruz","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.rbmo.2017.03.003","article-title":"Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study","volume":"34","author":"Cruz","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/humrep\/dey242","article-title":"ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE)","volume":"33","author":"De Geyter","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B30","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-016-0138-0","article-title":"Anti-M\u00fcllerian hormone serum level and other markers associated with pregnancy outcome in oocyte donation","volume":"14","author":"Delesalle","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"2021070807505486800_dmab008-B31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/1471-0528.14622","article-title":"The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial","volume":"124","author":"Dong","year":"2017","journal-title":"BJOG: Int J Obstet Gy"},{"key":"2021070807505486800_dmab008-B32","first-page":"CD006109","article-title":"Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques","volume":"5","author":"Farquhar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807505486800_dmab008-B33","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hox012","article-title":"The European IVF-Monitoring Consortium (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Trends over 15 years in ART in Europe: an analysis of 6 million cycles\u2020","volume":"2017","author":"Ferraretti","year":"2017","journal-title":"Hum Reprod Open"},{"key":"2021070807505486800_dmab008-B34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.rbmo.2018.08.018","article-title":"Revisiting the association between smoking and female fertility using the oocyte donation model","volume":"37","author":"Fr\u00e9our","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/09513590802404013","article-title":"Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial","volume":"25","author":"Galindo","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B36","author":"Galv\u00e3o","year":"2019"},{"key":"2021070807505486800_dmab008-B37","article-title":"Can serve medroxiprogesterone acetate (MPA) as pituitary suppressor instead of GnRH antagonist during ovarian stimulation (OS) in oocyte donation (OD) cycles trigger with GnRH agonist?","volume":"35","author":"Giles","year":"2020","journal-title":"Hum Reprod, Supp (Oxford, England"},{"key":"2021070807505486800_dmab008-B38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/humrep\/deaa003","article-title":"Effect of oocyte donor stimulation on recipient outcomes: data from a US national donor oocyte bank","volume":"35","author":"Hipp","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.fertnstert.2019.05.012","article-title":"Oocyte donor age has a significant impact on oocyte recipients\u2019 cumulative live-birth rate: a population-based cohort study","volume":"112","author":"Hogan","year":"2019","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B40","doi-asserted-by":"crossref","first-page":"e0145895","DOI":"10.1371\/journal.pone.0145895","article-title":"Elevated progesterone levels on the day of oocyte maturation may affect top quality embryo IVF cycles","volume":"11","author":"Huang","year":"2016","journal-title":"PLoS One"},{"key":"2021070807505486800_dmab008-B41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s10815-019-01494-x","article-title":"Is younger better? Donor age less than 25 does not predict more favorable outcomes after in vitro fertilization","volume":"36","author":"Humphries","year":"2019","journal-title":"J Assist Reprod Genet"},{"key":"2021070807505486800_dmab008-B43","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1093\/humrep\/det292","article-title":"IVF outcomes in obese donor oocyte recipients: a systematic review and meta-analysis","volume":"28","author":"Jungheim","year":"2013","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/humupd\/dmy016","article-title":"Ethics of oocyte banking for third-party assisted reproduction: a systematic review","volume":"24","author":"Kool","year":"2018","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.fertnstert.2013.09.007","article-title":"Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization\/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles","volume":"101","author":"Kuang","year":"2014","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B47","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/humrep\/deu175","article-title":"Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE","volume":"29","author":"Kupka","year":"2014","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B101"},{"key":"2021070807505486800_dmab008-B48","article-title":"Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)","volume":"2014","author":"Kwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807505486800_dmab008-B49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.fertnstert.2013.03.038","article-title":"Comparative analysis of fetal and neonatal outcomes of pregnancies from fresh and cryopreserved\/thawed oocytes in the same group of patients","volume":"100","author":"Levi Setti","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B50","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/humrep\/deg407","article-title":"GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles","volume":"18","author":"Lindheim","year":"2003","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/307174a0","article-title":"The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure","volume":"307","author":"Lutjen","year":"1984","journal-title":"Nature"},{"key":"2021070807505486800_dmab008-B52","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/09513590.2013.801443","article-title":"Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors?","volume":"29","author":"Mart\u00ednez","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.fertnstert.2014.07.741","article-title":"Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes","volume":"102","author":"Mart\u00ednez","year":"2014","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B54","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2020.01.016","article-title":"Does LH suppression by progesterone-primed ovarian stimulation compared with GnRH antagonist affect live birth rate among oocyte recipients?","author":"Mart\u00ednez","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/09513590801893331","article-title":"Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients","volume":"24","author":"Mart\u00ednez","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B56","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.fertnstert.2010.02.059","article-title":"Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors","volume":"94","author":"Mart\u00ednez","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.rbmo.2017.07.019","article-title":"Reproductive outcomes in recipients are not associated with oocyte donor body mass index up to 28\u2009kg\/m2: a cohort study of 2722 cycles","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B58","first-page":"1","article-title":"Desogestrel versus antagonist injections for LH suppression in oocyte donation cycles: a crossover study","author":"Mart\u00ednez","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B59","first-page":"1","article-title":"Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study","author":"Mart\u00ednez","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"2021070807505486800_dmab008-B60","first-page":"211","article-title":"New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF","volume":"23","author":"Massin","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B61","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.fertnstert.2007.10.065","article-title":"The incidence of both serious and minor complications in young women undergoing oocyte donation","volume":"90","author":"Maxwell","year":"2008","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B62","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.fertnstert.2009.05.005","article-title":"A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization","volume":"94","author":"Melo","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B63","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.rbmo.2009.06.001","article-title":"GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study","volume":"19","author":"Melo","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.fertnstert.2007.11.042","article-title":"Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte\/embryo quality or the in vitro fertilization outcome in an egg donation program","volume":"91","author":"Melo","year":"2009","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/humupd\/dmz037","article-title":"Ovarian stimulation for freeze-all IVF cycles: a systematic review","volume":"26","author":"Mizrachi","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2021070807505486800_dmab008-B66","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2021070807505486800_dmab008-B67","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/humrep\/dez299","article-title":"The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF\/ICSI cycles","volume":"35","author":"Montoya-Botero","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B68","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/humrep\/dez299","article-title":"The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF\/ICSI cycles","volume":"35","author":"Montoya-Botero","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rbmo.2009.10.009","article-title":"Anti-M\u00fcllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors","volume":"20","author":"Nakhuda","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B105"},{"key":"2021070807505486800_dmab008-B70","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/humrep\/deaa227","article-title":"Mild stimulation should be mandatory for oocyte donation","volume":"35","author":"Pennings","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B71","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.rbmo.2017.06.002","article-title":"Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes","volume":"35","author":"Pereira","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rbmo.2017.06.025","article-title":"Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors","volume":"35","author":"P\u00e9rez-Calvo","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B73","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.rbmo.2012.01.024","article-title":"Anti-M\u00fcllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors","volume":"24","author":"Polyzos","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B74","first-page":"CD009577","article-title":"Long-acting FSH versus daily FSH for women undergoing assisted reproduction","volume":"7","author":"Pouwer","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807505486800_dmab008-B75","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.fertnstert.2014.06.035","article-title":"Repetitive oocyte donation: a committee opinion","volume":"102","year":"2014","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B76","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/humrep\/deh832","article-title":"GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study","volume":"20","author":"Prapas","year":"2005","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B77","year":"2020"},{"key":"2021070807505486800_dmab008-B78","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/humrep\/dez238","article-title":"Do we need to measure progesterone in oocyte donation cycles? A retrospective analysis evaluating cumulative live birth rates and embryo quality","volume":"35","author":"Racca","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B79","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/humrep\/dey031","article-title":"Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality?","volume":"33","author":"Racca","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.rbmo.2012.11.015","article-title":"Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin \u03b1","volume":"26","author":"Requena","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"2021070807505486800_dmab008-B81","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/humrep\/deaa009","article-title":"Definition of a clinical strategy to enhance the efficacy, efficiency and safety of egg donation cycles with imported vitrified oocytes","volume":"35","author":"Rienzi","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B82","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.fertnstert.2010.07.1042","article-title":"Anti-M\u00fcllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation","volume":"95","author":"Riggs","year":"2011","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B84","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4471-2392-7","volume-title":"Principles of Oocyte and Embryo Donation","author":"Sauer","year":"2013","edition":"2nd ed"},{"key":"2021070807505486800_dmab008-B102"},{"key":"2021070807505486800_dmab008-B103"},{"key":"2021070807505486800_dmab008-B85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10815-009-9326-6","article-title":"Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial","volume":"26","author":"Sismanoglu","year":"2009","journal-title":"J Assist Reprod Genet"},{"key":"2021070807505486800_dmab008-B86","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/oxfordjournals.humrep.a019508","article-title":"A randomized comparative study of highly purified follicle stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in an oocyte donation programme","volume":"11","author":"S\u00f6derstr\u00f6m","year":"1996","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B87","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/humrep\/12.3.491","article-title":"Levonorgestrel-releasing intrauterine device can be used in oocyte donors during ovarian stimulation","volume":"12","author":"S\u00f6derstr\u00f6m-Anttila","year":"1997","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B88","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/det242","article-title":"How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes","volume":"28","author":"Sol\u00e9","year":"2013","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B89","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/det242","article-title":"How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes","volume":"28","author":"Sol\u00e9","year":"2013","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B90","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/humrep\/17.12.3129","article-title":"Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence","volume":"17","author":"Tesarik","year":"2002","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B91","doi-asserted-by":"crossref","first-page":"e0176482","DOI":"10.1371\/journal.pone.0176482","article-title":"Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF\/ICSI cycles","volume":"12","author":"Vanni","year":"2017","journal-title":"PLoS ONE"},{"key":"2021070807505486800_dmab008-B92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10815-010-9421-8","article-title":"Antral follice counts (AFC) predict ovarian response and pregnancy outcomes in oocyte donation cycles","volume":"27","author":"Vrontikis","year":"2010","journal-title":"J Assist Reprod Genet"},{"key":"2021070807505486800_dmab008-B93","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.fertnstert.2015.10.014","article-title":"Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study","volume":"105","author":"Vuong","year":"2016","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B94","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10815-017-0891-9","article-title":"Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles","volume":"34","author":"Vuong","year":"2017","journal-title":"J Assist Reprod Genet"},{"key":"2021070807505486800_dmab008-B95","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/humrep\/der359","article-title":"Donor age is a major determinant of success of oocyte donation\/recipient programme","volume":"27","author":"Wang","year":"2012","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B96","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.fertnstert.2019.06.009","article-title":"Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology","volume":"112","author":"Yildiz","year":"2019","journal-title":"Fertil Steril"},{"key":"2021070807505486800_dmab008-B97","first-page":"CD008046","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","volume":"10","author":"Youssef","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807505486800_dmab008-B98","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/humrep\/dex367","article-title":"New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF\/ICSI cycles","volume":"33","author":"Yu","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807505486800_dmab008-B99","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5935\/1518-0557.20170036","article-title":"Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial","volume":"21","author":"Zarcos","year":"2017","journal-title":"JBRA Assist Reprod"},{"key":"2021070807505486800_dmab008-B100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000909","article-title":"Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"94","author":"Zhu","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["Human Reproduction Update"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humupd\/article-pdf\/27\/4\/673\/38813999\/dmab008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humupd\/article-pdf\/27\/4\/673\/38813999\/dmab008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T15:31:04Z","timestamp":1625758264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humupd\/article\/27\/4\/673\/6179013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":102,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,3,20]]},"published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/humupd\/dmab008","relation":{},"ISSN":["1355-4786","1460-2369"],"issn-type":[{"value":"1355-4786","type":"print"},{"value":"1460-2369","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,3,20]]}}}